Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open label, balanced, randomized, two-treatment, two-period,
two-sequence, crossover bioequivalence study comparing a single oral dose of fenofibrate
capsules, USP 130 mg, of Ohm Laboratories Inc. USA (a subsidiary of Ranbaxy Pharmaceutical
Inc.) with Antara® (fenofibrate) Capsules 130 mg of Oscient Pharmaceuticals Corporation USA,
in healthy, adult, male, human subjects under fasting condition.